Importance of Clinical Trials Participation

Only about 5% of women with a gynecologic cancer participate in the dozens of clinical trials in gynecologic cancers. The predominant hope for improving on the treatment options for women diagnosed with a gynecologic cancer is through the conduct of clinical trials.

The Foundation for Women’s Cancer actively works with the Gynecologic Oncology Group (GOG) to encourage women to participate in clinical trials. Clinical trials are a crucial step in finding new and improved ways to improve treatment for women diagnosed with a gynecologic cancer.

Three examples of the important advances in the care of women as a result of clinical trials include:

  • Chemotherapy added to radiation improve cure rate in locally advanced cervical cancer (GOG 120, 109)
  • Platinum based chemotherapy plus paclitaxel is superior to platinum based chemotherapy plus cyclophosphamide (GOG 111)
  • IP therapy improves survival in subsets of women with newly diagnosed advanced ovarian cancer (GOG 172)

The patients that participated in the phase III clinical trials that led to these discoveries were among the first to benefit from these scientific advancements.


Thank you to Nat’l Race Chair Camille Grammer for hosting a successful event at her home to get the word out about the National Race to End Women’s Cancer!


The Foundation is featured in the Sept. issues of Coping, Women and Family Circle magazines. Look out for our articles & ads!


Research Prize applications are due 10/28. Click here to apply for one of the 7 available prizes.


The next Ovarian Cancer Survivors Course is Nov. 7 in Washington, D.C. For more information, click here.